DE10137174A1 - Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität - Google Patents
Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten ImmunitätInfo
- Publication number
- DE10137174A1 DE10137174A1 DE10137174A DE10137174A DE10137174A1 DE 10137174 A1 DE10137174 A1 DE 10137174A1 DE 10137174 A DE10137174 A DE 10137174A DE 10137174 A DE10137174 A DE 10137174A DE 10137174 A1 DE10137174 A1 DE 10137174A1
- Authority
- DE
- Germany
- Prior art keywords
- modification
- leads
- causing
- cell population
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Die Erfindung bezieht sich auf eine Verwendung von LHRH-Antagonisten bei gleichzeitiger kontrollierter Senkung des Sexualhormonspiegels. DOLLAR A Durch Verwendung von LHRH-Antagonisten zur Senkung des Sexualhormonspiegels wird eine Modifikation der T-Zellen-Population erreicht. DOLLAR A Mittels Steuerung der Dosis oberhalb eines Kastration bewirkenden Spiegels wird eine angestrebte Wirkung auf das Immunsystem erreicht.
Description
- In einem Patent von R. L. Boyd (WO 200062657, AU 200037977) behauptet der Autor, daß die Unterbrechung der Sexualsteroid-Signalübertragung durch Verabreichung eines LHRH-Agonisten bei Probanden mit einer geschwächten oder abnormalen T-Zellen-Population zu einer Modifikation der T-Zellen-Population führt. Diese Behandlung hat dann die unerwünschte Nebenwirkung, daß der Proband kastriert wird, der Autor behauptet jedoch, daß diese Kastration bei Abbruch der Behandlung reversibel ist.
- Diese Nebenwirkung ist äußerst unerwünscht, da er zu einem Verlust bzw. einer Verringerung der Libido, des Geschlechtsdrangs und der sexuellen Potenz führt. Bei Männern und bei Frauen vor der Menopause würde die Behandlung auch zu den typischen Symptomen führen, die bei der Erniedrigung des Sexualhormonspiegels unter den Kastration bewirkenden Spiegel auftreten, z. B. Wallungen, und Frauen würden zusätzlich Gefahr laufen, Knochenmineralien zu verlieren, was möglicherweise die Behandlungsdauer einschränkt.
- Diese unerwünschten Wirkungen könnten dadurch eingeschränkt werden, daß man einen LHRH-Antagonisten in solch einer Dosis verwendet, die nicht zu Kastration führt, jedoch noch die erwünschte Wirkung auf das Immunsystem ausübt.
Claims (7)
1. Verwendung eines peptidartigen oder
nichtpeptidartigen LHRH-Antagonisten in geeigneten
Dosen, die die Sexualhormonspiegel in gewissem
Ausmaß senken, jedoch nicht unterhalb den
Kastration bewirkenden Spiegel.
2. Verwendung eines LHRH-Antagonisten in geeigneten
Dosen zur Senkung der Sexualhormonspiegel, was zu
einer Modifikation der T-Zellen-Population führt.
3. Verwendung eines LHRH-Antagonisten in geeigneten
Dosen zur Senkung der Sexualhormonspiegel, was zu
einer Modifikation der T-Zellen-Population führt,
und zwar bei einem Patienten, der an einer
Krankheit leidet, die auf solch eine Modifikation
positiv anspricht.
4. Verwendung eines LHRH-Antagonisten in geeigneten
Dosen zur Senkung der Sexualhormonspiegel, was zu
einer Modifikation der T-Zellen-Population führt,
und zwar bei einem Patienten, der an einer HIV-
Infektion, an Krebs oder an einer
Autoimmunkrankheit leidet.
5. Verwendung eines LHRH-Antagonisten in geeigneten
Dosen zur Senkung der Sexualhormonspiegel, was zu
einer Modifikation der T-Zellen-Population führt,
was zu einer verbesserten Immunreaktion auf ein
Antigen führt.
6. Verwendung eines LHRH-Antagonisten in geeigneten
Dosen zur Senkung der Sexualhormonspiegel, was zu
einer Modifikation der T-Zellen-Population führt,
was zu einer verringerten Host-versus-Graft-
Reaktion führt.
7. Substanzen, die als LHRH-Antagonisten in der
vorliegenden Erfindung verwendet werden können,
sind zum Beispiel Cetrorelix, Teverelix, Antide
oder Abarelix.
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10137174A DE10137174A1 (de) | 2001-07-31 | 2001-07-31 | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| IL15928502A IL159285A0 (en) | 2001-07-31 | 2002-07-30 | Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity |
| PL02364492A PL364492A1 (en) | 2001-07-31 | 2002-07-30 | Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity |
| DE60208701T DE60208701T2 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
| KR10-2004-7001327A KR20040028957A (ko) | 2001-07-31 | 2002-07-30 | Ｔ-세포 매개된 면역 개선용 ｌｈｒｈ-길항제의 용도 |
| AT02767276T ATE315400T1 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
| NZ531263A NZ531263A (en) | 2001-07-31 | 2002-07-30 | Use of cetrorelix to induce an enhanced or decreased immune response without lowering sex hormones to levels below castration level |
| CNA028136993A CN1525865A (zh) | 2001-07-31 | 2002-07-30 | Lhrh-拮抗剂改善t细胞介导的免疫反应的应用 |
| PCT/EP2002/008459 WO2003011314A2 (en) | 2001-07-31 | 2002-07-30 | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| JP2003516544A JP2005500348A (ja) | 2001-07-31 | 2002-07-30 | Ｔ細胞介在免疫を向上させる際の、去勢状態を誘発しない量でのｌｈｒｈ−拮抗剤の使用 |
| MXPA04000870A MXPA04000870A (es) | 2001-07-31 | 2002-07-30 | Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t. |
| RU2004106545/15A RU2004106545A (ru) | 2001-07-31 | 2002-07-30 | Применение антагонистов lhrh для модулирования t-клеточно-опосредованного иммунитета (варианты) |
| HU0401634A HUP0401634A2 (hu) | 2001-07-31 | 2002-07-30 | LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására |
| EP02767276A EP1414481B1 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
| CA002452524A CA2452524A1 (en) | 2001-07-31 | 2002-07-30 | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| BR0211498-4A BR0211498A (pt) | 2001-07-31 | 2002-07-30 | Uso de antagonistas de lhrh em doses que não causam castração, para a melhora de imunidade mediada por células t |
| ARP020102902A AR034954A1 (es) | 2001-07-31 | 2002-07-31 | Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t |
| ZA200309889A ZA200309889B (en) | 2001-07-31 | 2003-12-22 | Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity. |
| NO20040350A NO20040350L (no) | 2001-07-31 | 2004-01-26 | Anvendelse av LHRH-antagonister i doser som ikke medfører kastrering, for forbedring av T-cellemediert immunitet. |
| HR20040186A HRP20040186B1 (en) | 2001-07-31 | 2004-02-25 | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10137174A DE10137174A1 (de) | 2001-07-31 | 2001-07-31 | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10137174A1 true DE10137174A1 (de) | 2003-02-13 |
Family
ID=7693650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10137174A Withdrawn DE10137174A1 (de) | 2001-07-31 | 2001-07-31 | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| DE60208701T Expired - Fee Related DE60208701T2 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60208701T Expired - Fee Related DE60208701T2 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1414481B1 (de) |
| JP (1) | JP2005500348A (de) |
| KR (1) | KR20040028957A (de) |
| CN (1) | CN1525865A (de) |
| AR (1) | AR034954A1 (de) |
| AT (1) | ATE315400T1 (de) |
| BR (1) | BR0211498A (de) |
| CA (1) | CA2452524A1 (de) |
| DE (2) | DE10137174A1 (de) |
| HR (1) | HRP20040186B1 (de) |
| HU (1) | HUP0401634A2 (de) |
| IL (1) | IL159285A0 (de) |
| MX (1) | MXPA04000870A (de) |
| NO (1) | NO20040350L (de) |
| NZ (1) | NZ531263A (de) |
| PL (1) | PL364492A1 (de) |
| RU (1) | RU2004106545A (de) |
| WO (1) | WO2003011314A2 (de) |
| ZA (1) | ZA200309889B (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL147138A0 (en) * | 2001-12-17 | 2002-08-14 | Yeda Res & Dev | Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation |
| EP1891964A1 (de) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Anwendung von Anfangsdosen von LHRH-Analogen und Erhaltungsdosen von LHRH-Antagonisten zur Behandlung von hormonabhängigen Krebsarten und entsprechende Kits |
| WO2009033792A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| WO2009033781A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| EP2095818A1 (de) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen |
| EP2379099A1 (de) * | 2009-01-22 | 2011-10-26 | Maatschap Interne Geneeskunde Rijnstate | Verfahren zur prophylaxe oder behandlung von hitzewallungen |
| EP3185881B1 (de) | 2014-08-26 | 2022-03-09 | Betanien Hospital | Verfahren, wirkstoffe und zusammensetzungen zur behandlung von entzündlichen erkrankungen |
| CN107007814B (zh) * | 2016-11-04 | 2020-03-17 | 中国科学院昆明动物研究所 | 西曲瑞克在制备治疗艾滋病的药物中的应用 |
| CN108066763A (zh) * | 2017-12-21 | 2018-05-25 | 陈敏 | Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004479A1 (en) * | 1989-09-25 | 1991-04-04 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Evaluative means for detecting inflammatory reactivity and for predicting response to stress |
| DE4320201A1 (de) * | 1993-06-18 | 1995-01-12 | Asta Medica Ag | Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation |
| DE4342091A1 (de) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
| IL114655A (en) * | 1994-07-22 | 2005-08-31 | Hampton Roads Medical College | USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL |
| AU3361695A (en) * | 1994-08-10 | 1996-03-07 | Dezso Gaal | Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof |
| WO1996022786A1 (en) * | 1995-01-23 | 1996-08-01 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and use |
| US5780435A (en) * | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
| US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
| AU747807B2 (en) * | 1997-11-24 | 2002-05-23 | Apollo Biopharmaceutics Inc. | Testosterone inhibitors and use for the protection of neurons |
| US20020119128A1 (en) * | 2000-04-17 | 2002-08-29 | Richard Boyd | Graft acceptance through manipulation of thymic regeneration |
| US20020071829A1 (en) * | 1999-04-15 | 2002-06-13 | Richard Boyd | Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| CA2406832A1 (en) * | 2000-04-13 | 2002-10-10 | Takeda Chemical Industries, Ltd. | Preventives/remedies for alzheimer's disease |
| US7288517B2 (en) * | 2001-04-30 | 2007-10-30 | Aeterna Zentaris Gmbh | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
-
2001
- 2001-07-31 DE DE10137174A patent/DE10137174A1/de not_active Withdrawn
-
2002
- 2002-07-30 PL PL02364492A patent/PL364492A1/xx unknown
- 2002-07-30 MX MXPA04000870A patent/MXPA04000870A/es unknown
- 2002-07-30 HU HU0401634A patent/HUP0401634A2/hu unknown
- 2002-07-30 NZ NZ531263A patent/NZ531263A/en unknown
- 2002-07-30 JP JP2003516544A patent/JP2005500348A/ja not_active Withdrawn
- 2002-07-30 CN CNA028136993A patent/CN1525865A/zh active Pending
- 2002-07-30 RU RU2004106545/15A patent/RU2004106545A/ru not_active Application Discontinuation
- 2002-07-30 AT AT02767276T patent/ATE315400T1/de not_active IP Right Cessation
- 2002-07-30 WO PCT/EP2002/008459 patent/WO2003011314A2/en active IP Right Grant
- 2002-07-30 IL IL15928502A patent/IL159285A0/xx unknown
- 2002-07-30 EP EP02767276A patent/EP1414481B1/de not_active Expired - Lifetime
- 2002-07-30 DE DE60208701T patent/DE60208701T2/de not_active Expired - Fee Related
- 2002-07-30 BR BR0211498-4A patent/BR0211498A/pt not_active IP Right Cessation
- 2002-07-30 CA CA002452524A patent/CA2452524A1/en not_active Abandoned
- 2002-07-30 KR KR10-2004-7001327A patent/KR20040028957A/ko not_active Application Discontinuation
- 2002-07-31 AR ARP020102902A patent/AR034954A1/es unknown
-
2003
- 2003-12-22 ZA ZA200309889A patent/ZA200309889B/en unknown
-
2004
- 2004-01-26 NO NO20040350A patent/NO20040350L/no not_active Application Discontinuation
- 2004-02-25 HR HR20040186A patent/HRP20040186B1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AR034954A1 (es) | 2004-03-24 |
| CN1525865A (zh) | 2004-09-01 |
| HRP20040186B1 (en) | 2007-05-31 |
| IL159285A0 (en) | 2004-06-01 |
| EP1414481A2 (de) | 2004-05-06 |
| ATE315400T1 (de) | 2006-02-15 |
| HRP20040186A2 (en) | 2004-08-31 |
| CA2452524A1 (en) | 2003-02-13 |
| NO20040350L (no) | 2004-01-26 |
| ZA200309889B (en) | 2004-02-19 |
| RU2004106545A (ru) | 2005-04-10 |
| BR0211498A (pt) | 2004-08-17 |
| DE60208701T2 (de) | 2006-08-10 |
| WO2003011314A3 (en) | 2003-10-16 |
| DE60208701D1 (de) | 2006-04-06 |
| PL364492A1 (en) | 2004-12-13 |
| EP1414481B1 (de) | 2006-01-11 |
| KR20040028957A (ko) | 2004-04-03 |
| HUP0401634A2 (hu) | 2004-12-28 |
| NZ531263A (en) | 2005-05-27 |
| MXPA04000870A (es) | 2004-06-03 |
| JP2005500348A (ja) | 2005-01-06 |
| WO2003011314A2 (en) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krulich et al. | The effects of acute stress on the secretion of LH, FSH, prolactin and GH in the normal male rat, with comments on their statistical evaluation | |
| Neill et al. | Luteinizing hormone releasing hormone (LHRH) in pituitary stalk blood of rhesus monkeys: relationship to level of LH release | |
| Cagampang et al. | Involvement of ovarian steroids and endogenous opioids in the fasting-induced suppression of pulsatile LH release in ovariectomized rats | |
| ZELEZNIK et al. | Ovarian responses in macaques to pulsatile infusion of follicle-stimulating hormone (FSH) and luteinizing hormone: increased sensitivity of the maturing follicle to FSH | |
| Mason et al. | Induction of ovulation with pulsatile luteinising hormone releasing hormone. | |
| Ben-Rafael et al. | Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation | |
| Hoffmann et al. | Reproductive endocrinology of bitches | |
| Clarke et al. | Pituitary Receptors for Gonadotropin-Releasing Hormone in Relation to Changes in Pituitary and Plasma Gonadotropins in Ovariectom ized Hypothalamo/Pituitary-Disconnected EWES. II. A Marked Rise in Receptor Number during the Acute Feedback Effects of Estradiol | |
| Rajendren et al. | Role of the vomeronasal organ in the male-induced enhancement of sexual receptivity in female rats | |
| D’Occhio et al. | Characteristics of luteinizing hormone (LH) and testosterone secretion, pituitary responses to LH-releasing hormone (LHRH), and reproductive function in young bulls receiving the LHRH agonist deslorelin: effect of castration on LH responses to LHRH | |
| DE10137174A1 (de) | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität | |
| Bellows et al. | Dose-response relationships in synchronized beef heifers treated with follicle stimulating hormone | |
| BADGER et al. | Hypothalamic-pituitary function in adult rats treated neonatally with monosodium glutamate | |
| Lanzone et al. | LH surge induction by GnRH agonist at the time of ovulation | |
| DE69831241T2 (de) | Gonadotropin freisetzendes Hormon Antagonist | |
| CHEESMAN et al. | Suppression of the preovulatory surge of luteinizing hormone and subsequent ovulation in the rat by arginine vasotocin | |
| DE60010452T2 (de) | Programmierte ovarielle stimulationsbehandlungprotokoll unter verwendung von oralen kontrazeptiva | |
| Besecke et al. | Acute increase in responsiveness of luteinizing hormone (LH)-releasing hormone nerve terminals to neuropeptide-Y stimulation before the preovulatory LH surge | |
| Watanabe et al. | Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women | |
| Brzuska et al. | Artificial spawning of carp Cyprinus carpio L.: differences between the effects on reproduction in females of Israeli strain Dor‐70 and its cross‐breed treated with carp pituitary and Ovopel | |
| Depalo et al. | Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer | |
| Germain et al. | Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight-recovered anorexia nervosa patients | |
| Menzies et al. | Immunological control of congenital toxoplasmosis in the murine model | |
| Mutayoba et al. | Effects of Trypanosoma congolense infection in rams on the pulsatile secretion of LH and testosterone and responses to injection of GnRH | |
| Shi et al. | Serous cysts are a benign component of the cyclic ovary in the guinea pig with an incidence dependent upon inhibin bioactivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: ZENTARIS GMBH, 60314 FRANKFURT, DE |
|
| 8130 | Withdrawal | ||
| 8127 | New person/name/address of the applicant |
Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE |